Ruben Collado-Pavia
Madrid, MD 28029, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Intracerebral administration of a modified antisense oligonucleotide targeting the dopamine system in a mouse model of Parkinson's disease.
Journal: STAR protocols
Published: June 16, 2022
Up and Down γ-Synuclein Transcription in Dopamine Neurons Translates into Changes in Dopamine Neurotransmission and Behavioral Performance in Mice.
Journal: International journal of molecular sciences
Published: January 10, 2022
Corrigendum to "Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys" [EBioMedicine 2020; 59:102944].
Journal: EBioMedicine
Published: December 01, 2021
Human α-synuclein overexpression in mouse serotonin neurons triggers a depressive-like phenotype. Rescue by oligonucleotide therapy.
Journal: Translational psychiatry
Published: July 26, 2021
Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
Journal: International journal of molecular sciences
Published: February 09, 2021
Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys.
Journal: EBioMedicine
Published: February 17, 2020
Selective α-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson's Disease.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: March 06, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026